MOLOGEN presents overall result for the year:

Successful projects and sound financing provide solid basis for future growth

MOLOGEN AG (ISIN DE0006637200) has closed the fiscal year with financial figures characteristic for a biotech enterprise with a focus on research. The preparatory work and measures implemented over the past months, the latest developments, and a further improved financial situation with better liquidity form a solid basis for MOLOGEN’s positive economic and operational development in 2006.

Net sales in the past fiscal year 2005 amounted to 0.8 million , following 2.1 million € in 2004. EBIT was -4.1 million €, after -2.1 million € in 2004, and the overall result for the year 2005 was -4.4 million €, after -2.1 million € in the previous year. The financial figures for the year 2005 were influenced significantly by the company’s decision to focus on the location-independent license business in the area of cell-based gene therapy. This decision was taken after the end of the fiscal year, and with a conscious acceptance that it would incur non-recurring expenses and depreciations for 2005 resulting from the termination of the Arabic joint venture INMOG.

Liquid assets increased from 2.3 million € in 2004 to 7.8 million € in the fiscal year 2005.
Especially the latest developments, which imply a paradigm shift, give MOLOGEN solid reason to expect an improved turnover and result situation in the near future. MOLOGEN has laid the technological foundation for such a development with the successful research results in the past fiscal year. At the same time, MOLOGEN has been successful in achieving progress in other areas as well, such as the development and optimization of a vaccine against leishmaniosis, thus coming closer to a profitable marketing.

Download Consolidated financial statements for the fiscal year 2005

About MOLOGEN

MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview